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Summary
Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the
safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhibitor, in an expansion cohort of patients
with adenoid cystic carcinoma (ACC) who received the dose-escalation-recommended phase 2 dose (RP2D), established previ-
ously (Massard C, et al., Annals Oncol 2018, 29:1911–17). Methods Patients with advanced or metastatic cancer, measurable
disease, ECOG-PS ≤1, and baseline tumor tissuewere enrolled. Primary objectives were to identify a safe RP2D, confirm this dose
in expansion cohorts, and document anti-tumor activity. Secondary objectives included safety and progression-free survival (PFS).
The ACC expansion cohort received the RP2D regimen of 50 mg crenigacestat thrice per week in a 28-day cycle until disease
progression or other discontinuation criteria were met. Results Twenty-two patients with ACC were enrolled in the expansion
cohort (median age of 60 years). Median treatment duration was 3 cycles with 6 patients remaining on treatment. There were no
objective responses; 1 (5%) patient had an unconfirmed partial response. Disease control rate was 73% and 4 patients had stable
disease ≥6 months. Median PFS was 5.3 months (95%CI: 2.4-NE)) for the 22 patients; and 7.7 months (95%CI: 4.0-NR) and
2.4 months (95%CI: 1.1-NE) in the subgroup of patients in second-line (n = 7) or ≥ third-line (n = 9), respectively. Frequent
treatment-related-adverse events (all grades) included diarrhea, fatigue, vomiting, decreased appetite, dry mouth, and dry skin.
There were no new safety signals. Conclusion The crenigacestat RP2D regimen induced manageable toxicity and limited clinical
activity, without confirmed responses, in heavily pretreated patients with ACC.
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Introduction
Adenoid cystic carcinoma (ACC) is a rare form of carcinoma
characterized by slow growth, frequent recurrences, and a
high incidence of metastasis. Surgical resection followed by
radiation is the most common treatment protocol; to date, no
chemotherapy or drug combination is effective [1, 2].
Notch signaling is an evolutionarily conserved pathway
that plays an integral role in development and tissue homeo-
stasis [3, 4]. The oncogenic functions of Notch signaling in-
clude the inhibition of apoptosis and the promotion of cell
proliferation [5–13]. Recent studies suggest that Notch1 plays
a key role in the cell growth and metastasis of ACC, and
patients with Notch1 mutations appear to have a more aggres-
sive disease with a distinct pattern of metastasis and worse
prognosis [14–16]. Thus, targeting Notch1 represents a poten-
tial therapeutic strategy.
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Crenigacestat is a potent small molecule inhibitor of Notch
cleavage that prevents release of the notch intracellular do-
main (NICD) by inhibiting proteolytic activity of γ-secretase
complex and thereby decreasing Notch signaling and its
downstream biologic effects. Crenigacestat inhibits tumor
growth in patient-derived tumors representing colon, lung,
ovarian, gastric, breast cancer, non-small cell lung cancer,
and glioblastoma [17].
Study I6F-MC-JJCA was designed and conducted as a
phase 1, nonrandomized, open-label, multicenter trial that
evaluated the safety and antitumor activity of crenigacestat
in patients with advanced or metastatic cancers. In the dose
escalation part of this trial, crenigacestat was well tolerated at
doses engaging the Notch receptor in heavily pre-treated pa-
tients, including patients with ACC [18]. Crenigacestat expo-
sure was dose proportional. Preliminary pharmacodynamic
analyses showed that at a starting dose of 45 mg administered
3 times per week (TIW) in a 28-day cycle, crenigacestat in-
hibits Notch-regulated gene expression by approximately
50%. Compared with the 75 mg dose, the 50 mg dose was
associated with milder to moderate severity of adverse events,
commonly diarrhea and vomiting, and a few grade 3 or 4
events. Clinical benefit was observed in 11% of the patients.
Thus, given the relative safety/tolerability and potential for
clinical benefit/anti-tumor activity, the recommended phase
2 dose (RP2D) of crenigacestat monotherapy was determined
as 50 mg administered 3 TIW in a 28-day cycle [18].
Here, we report the safety, tolerability and anti-tumor ac-
tivity of crenigacestat monotherapy in the confirmatory, ex-
pansion cohort of patients with ACC enrolled in I6F-MC-
JJCAwho were treated with the RP2D.
Methods
Study design and treatment
I6F-MC-JJCA was a phase 1 multi-center, nonrandomized,
open-label, first-in-man trial of oral crenigacestat
(LY3039478), in patients with advanced or metastatic cancer
(ClinicalTrials.gov identifier: NCT01695005). Primary objec-
tives were to evaluate the safety of crenigacestat in a dose-
escalation phase and determine a RP2D, to confirm the RP2D
of crenigacestat in the expansion cohort, and to document
anti-tumor activity. Secondary objectives included character-
izing the safety and toxicity profile of crenigacestat and
assessing the duration of response and progression-free sur-
vival (PFS). Exploratory objectives examined potential
predictive biomarkers, pharmacodynamic effects of
crenigacestat, and utility of positron emission tomography
(PET) scan to assess the treatment effect of crenigacestat.
In the confirmatory, expansion cohort, patients received the
RP2D of 50 mg crenigacestat TIW in 28-day cycles until
symptomatic or confirmed progressive disease, unacceptable
toxicity, or other study drug discontinuation criteria were met.
This study was conducted in compliance with the
Declaration of Helsinki, Council for International
Organizations of Medical Sciences International Ethical
Guidelines, International Conference on Harmonization
Guidelines for Good Clinical Practice, and applicable local
regulations. The ethics committees of all participating centers
approved the protocol, and all patients provided written in-
formed consent before study entry.
Patients
Eligible patients were ≥ 18 years of age and had histological
evidence of advanced or metastatic ACC. All patients had
measurable disease or reliable biomarker measure. Patients
had an Eastern Cooperative Oncology Group performance
status (ECOG-PS) score of ≤1, adequate organ and hemato-
logic functions. Patients were excluded from the study if they
had received treatment with a drug that had not received reg-
ulatory approval for any indication within 14 or 21 days of the
initial dose of study drug and had any serious pre-existing
medical conditions. Patients were also excluded if they had
any central nervous system malignancy, acute leukemia, or if
they had undergone any autologous or allogeneic stem-cell
transplantation.
Study assessments
Efficacy assessments Tumor responses were measured using
the appropriate guidelines (RECIST 1.1) [19]. Objective re-
sponse rate (ORR) was the proportion of patients who
achieved a complete response (CR), partial response (PR), or
stable disease (SD) out of all the patients who received at least
1 dose of study drug. Best response was determined from a
sequence of responses assessed. Minimum change in tumor
size from baseline was presented in a waterfall plot for patients
with measureable lesion.
Use of PET scan to assess treatment effect of crenigacestat
was mandatory for the ACC expansion cohort. Partial meta-
bolic response by PETscanwas defined as a minimum of 15%
in tumor [18F]-FDG SUVafter 1 cycle of therapy and greater
than 25% after more than 1 treatment cycle, according to PET
response criteria of the European Organization for Research
and Treatment of Cancer [20].
Safety assessments All adverse events (AEs) were coded ac-
cording to the Medical Dictionary for Regulatory Activities,
version 19.0 and graded by National Cancer Institute’s (NCI)
Common Terminology Criteria for Adverse Events (CTCAE)
4.0. Dose-limiting toxicity (DLT) was defined as an AE dur-
ing Cycle 1 that is related to crenigacestat and fulfills any one
of the following criteria using the NCI CTCAE v 4.0: ≥3
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CTCAE Grade 3 nonhematological toxicity (exceptions made
for nausea, vomiting, or constipation that lasts <72 h and can
be controlled with treatment; transient Grade 3 elevations of
ALT and/or AST), CTCAE Grade 4 hematological toxicity of
>5 days duration, any febrile neutropenia, Grade 3 thrombo-
cytopenia with bleeding or Grade 4 thrombocytopenia, and
other significant toxicity deemed to be dose limiting by
investigator.
Pharmacokinetic assessments Crenigacestat PK parameter es-
timates for patients were summarized and compared to PK
parameters from the dose-escalation phase of the trial.
Plasma samples were collected up to 4 h after the first dose
for PK evaluation.
Exploratory biomarker assessments Patients in the study sub-
mitted representative pre-treatment archival diagnostic biop-
sies as formalin-fixed, paraffin-embedded (FFPE) tissue, with
some patients submitting pre- and post-treatment biopsies col-
lected in formalin or PAXgene® Tissue Fix. Specimens were
sectioned at 4–5 μm (if submitted as blocks) onto positively
charged slides and baked at 60 °C for at least 15 min or until
dry. De-paraffinization and antigen retrieval were accom-
plished using EnVision™ FLEX Target Retrieval Solution,
High pH (K8000; Dako, Carpinteria, CA, USA) in a Dako
PT Link unit reaching 97 °C for 20 min. The retrieved
NICD was detected using the Dako EnVision™ FLEX+
Rabbit visualization system (K8009) on the Dako
Autostainer Link 48 automated slide stainer with proprietary
1.5 μg/mL N1ICD, 2.0 μg/mL N2ICD, or 2.0 μg/mL N3ICD
antibody developed for Eli Lilly and Company. Results were
interpreted and scored by a board-certified pathologist (GJO).
Specimens were scrutinized for the level of endogenous back-
ground signal by examining additional sections using an
isotype control. Control tissues were processed in parallel with
tissues exposed to primary antibody. Immunohistochemistry
(IHC) results were scored by a qualitative method based on an
assessment of the immunoreactivity observed in the specimen
using a scale of 0 to 3+ translating to no (0), weak (1+),
moderate (2+), or intense (3+) staining, respectively. A cut-
off of ≥10% tumor cells with specific nuclear staining with
≥1+ immunoreactivity was used to determine positive
immunoreactivity.
Statistical analyses
Data from all patients who received at least 1 dose of
crenigacestat treatment were included in summaries of safety
and efficacy. Analyses of safety and efficacy were based on
October 2016 data transfer.
Change in tumor size was assessed in each patient with
measurable disease using radiographic imaging. The mini-
mum change in tumor size was summarized for all patients
with a pre- and post-treatment assessment using a waterfall
plot. For patients evaluated by PETscan, the minimum change
in SUVmax was summarized using a waterfall plot. ORR and
PET metabolic response rates were summarized descriptively.
Descriptive analyses of PFS and OS were conducted using the
Kaplan-Meier method. Plasma and urine concentrations were
measured using validated LC/MS/MC methods.
Table 1 Patient and disease characteristics
Characteristics N = 22, n (%)
Gender
Male 13 (59%)
Female 9 (41%)
Age, years, median (range) 60 (41–82)
Race
White 19 (86%)
African American 1 (5%)
Missing 2 (9%)
ECOG
0 4 (18%)
1 18 (82%)
Prior therapy
Surgery 14 (64%)
Radiotherapy 20 (91%)
Prior systemic treatments
0 6 (27%)
1 7 (32%)
≥ 2 9 (41%)
Metastatic Disease 22 (100%)
Sites of metastases
Lung 20 (91%)
Bone 8 (36%)
Liver 5 (23%)
Lymph node 5 (23%)
Notch ICD IHC
Positive 14 (64%)
Negative 8 (36%)
ECOG, Eastern Cooperative Oncology Group; NICD, Notch-1
intracellular domain
Table 2 Summary of best overall response
N = 22
n (%)
Partial response (unconfirmed) 1 (5%)
Stable disease (SD) 15 (68%)a
Progressive disease (PD) 5 (23%)
Not evaluable 1
Disease control rate (CR + PR+ SD) 16 (73%)
a 4 patients had stable disease ≥6 months
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Results
Patient characteristics
Twenty-two patients with ACC were treated with
crenigacestat monotherapy (Table 1) of which 13
(59%) were male and 9 (41%) were female. The ma-
jority (82%) of patients had ECOG-PS 1. Median age
was 60 years (range 41–82). 20 (91%) patients had
prior radiotherapy and 9 (41%) patients received two
or more prior systemic treatments. All patients had
metastatic disease and 14 (64%) patients were positive
for Notch 1.
Efficacy
Median treatment duration was 3 cycles (range 1–10)
with 6 patients remaining on treatment. 1 (5%) patient
had an unconfirmed partial response. A total of 15
(68%) patients had stable disease of which 4 patients
had stable disease for ≥6 months. 5 (23%) patients
had progressive disease. Disease control rate (DCR)
was 73% (16 out of 22 patients) (Table 2). In the over-
all group (n = 22), median PFS was 5.3 months (95%
CI: 2.4-NE) (Fig. 1). Median PFS was 7.7 (95% CI:
4.0-NE) for patients in second line therapy (n = 7),
while it was 2.4 (95% CI: 1.1- NE) for patients in third
line or more (n = 9). In patients without prior systemic
therapy (n = 6), median PFS could not be estimated
since 4 of those patients were censored (Fig. 2).
Patient disposition
At the time of data cut off, 6 out of 22 patients were
still on treatment and 16 patients had discontinued the
treatment (Fig. 3). A total of 8 patients discontinued
due to progressive disease while 4 patients discontinued
due to investigator’s decision. Other reasons for discon-
tinuation were AEs (n = 2; 1 patient discontinued due to
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Fig. 1 Progression-free survival
Fig. 2 Progression-free survival
by lines of prior systemic
therapies
emergence of a squamous cell skin carcinoma), with-
drawal by subject (n = 1), or death (n = 1; sudden death
unrelated to study drug).
Safety and tolerability
The majority of AEs in all the patients receiving crenigacestat
were mild to moderate in severity, with a few patients
experiencing Grade 3/4 events. 3 (13.6%) patients experienced
Grade 3/4 diarrhea. Hypophosphatemia, colitis, nausea, fa-
tigue, increased ALT, increased AST, increased blood creati-
nine, and dehydration were the most common Grade 3/4 AEs,
which occurred in at least 1 patient. There were 2 (9.1%) pa-
tients who reported Grade 3/4 squamous cell carcinoma of
skin. Most frequent treatment-emergent drug related adverse
events (all grades) occurring in ≥10% of patients were diarrhea
(n = 12; 55%), fatigue (n = 10; 45%), vomiting (n = 8; 36%),
dry mouth (n = 6; 27%), decreased appetite (n = 6; 27%), dry
skin (n = 5; 23%), hypophosphatemia (n = 4; 18%), stomatitis
(n = 4; 18%), nausea (n = 4; 18%), dysgeusia (n = 4; 18%), hair
color changes (n = 4; 18%), pyrexia (n = 3; 14%), increased
ALT (n = 3; 14%), decreased weight (n = 3; 14%), alopecia
(n = 3; 14%), and rashes (n = 3; 14%) (Table 3).
Fig. 3 Tumor response over time.
uPR = unconfirmed partial
response, SD = stable disease,
PD = progressive disease, NA=
not available
Table 3 Most frequent related adverse events (≥10% of patients)
Adverse events Investigator-determined
Maximum CTC Grade, n (%)
N = 22
n (%)
Grade 1 Grade 2 Grade 3 Grade 4
Diarrhea 3 (14) 6 (27) 3 (14) – 12 (55)
Fatigue 6 (27) 3 (14) 1 (5) – 10 (45)
Vomiting 4 (18) 4 (18) – – 8 (36)
Dry mouth 6 (27) – – – 6 (27)
Decreased appetite 3 (14) 3 (14) – – 6 (27)
Dry skin 4 (18) 1 (5) – – 5 (23)
Hypophosphatemia 2 (9) 2 (9) – – 4 (18)
Dysgeusia 4 (18) – – – 4 (18)
Stomatitis 3 (14) 1 (5) – – 4 (18)
Nausea 2 (9) 2 (9) – – 4 (18)
Hair color changes 3 (14) 1 (5) – – 4 (18)
Pyrexia 3 (14) – – – 3 (14)
ALT increased 1 (5) 1 (5) 1(5) – 3 (14)
Weight decreased 1 (5) 2 (9) – – 3 (14)
Alopecia 3 (14) – – – 3 (14)
Rash 3 (14) – – – 3 (14)
ALT, Alanine aminotransferase
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Pharmacokinetics
PK was assessed in 17 patients, with maximum plasma con-
centrations (Cmax) occurring approximately 2 h post-dose fol-
lowing 50 mg TIWoral doses of crenigacestat. The geometric
mean Cmax was approximately 418 ng/mL and area under the
plasma concentration time curve from time 0 to 4 h [AUC(0–4)]
was approximately 1070 ng*h/mL. These PK parameters ap-
peared similar to those calculated from patients who
underwent intensive PK sampling in the dose-escalation por-
tion of I6F-MC-JJCA and the exposures achieved were simi-
lar to other patients with advanced cancer.
Exploratory biomarker and pharmacodynamics analyses
Pre- and post-treatment tumor biopsies were assessed for al-
terations in the Notch pathway. Notch activation via detection
of the active NICD fragment by IHCwas found in a number of
pre-treatment samples. 14 out of 22 (64%) patients with
evaluable samples were positive for Notch 1 IHC. Two pa-
tients had pre- and post-treatment biopsies, which were
evaluable. In the post-treatment samples, 1 patient was nega-
tive for Notch staining and the other was positive. Duration of
stable disease in these patients was 3.5 months and 6 months,
respectively. Pre- and post-treatment tumor biopsies (histolo-
gy and CD8IHC) are illustrated in Fig. 4.
In preliminary analysis, 16 patients were assessed for min-
imum change in SUVmax by PET, of which 2 (13%) had un-
confirmed partial metabolic response (Fig. 5).
Discussion
This report describes the phase I safety, tolerability, and clin-
ical activity of crenigacestat, a highly potent and selective
Notch inhibitor of ACC. We have established that
crenigacestat can be administered safely on a TIW schedule
at a dose of 50 mg in patients with ACC. Grade 3/4 toxicities
were low. Similar to the patients in the previously reported
dose escalation and other dose expansion cohorts reported
for this trial [18, 21], gastrointestinal toxicity (diarrhea and
nausea) was the major toxicity observed in these patients.
These events were consistent with the previously reported
clinical safety profile for Notch pathway inhibitors.
There were no objective partial or complete responses.
However, a majority of the patients (58%) with ACC achieved
stable disease and 4 patients among them had stable disease
for more than 6 months despite the patient population being
Fig. 4 Pre- and post-treatment
tumor biopsies (Notch IHC).
Duration of stable disease
3.5 months. *This was accessed
only in one patient. So, further
evaluation in future is needed
Fig. 5 Minimum Change in
SUVmax by PETAssessment
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heterogeneous and heavily pretreated, with more than 40%
receiving crenigacestat monotherapy as second line or greater.
Yet, ACC is unique in its unpredictable, yet slow-growing,
nature [22]. Despite this and the fact that these patients were
heavily pre-treated, overall, disease control rate was 73% (16/
22). Two out of 16 (13%) patients demonstrated unconfirmed
partial metabolic response evidenced by reduction in PET
SUVmax. The geometric mean Cmax and area under plasma
concentration time curve appeared similar to those calculated
from patients who underwent intensive PK sampling in the
dose-escalation phase.
A change in Notch expression pattern was observed in
patients who underwent pre- and post-treatment biopsies,
which may be consistent with pharmacologic activity; how-
ever, samples were submitted in several types of fixative,
which could impact the sensitivity and specificity for activa-
tion of Notch by IHC. The high level of Notch activation in
our patient cohort’s pre-treatment samples is consistent with
recent studies of Notch activation prevalence in ACC [23, 24],
Differences seen, i.e., the slightly lower percentage observed,
however, may be due to fixation techniques and IHC antibody
clones.
In summary, the results of the ACC expansion cohort in
this phase 1 trial demonstrate that crenigacestat has a manage-
able safety profile and a clinical pharmacodynamic effect on
Notch-targeted genes. However, crenigacestat clinical activity
was limited at the recommended dose with no confirmed ob-
jective response. Trials are ongoing to explore crenigacestat in
combination with targeted agents and chemotherapy. Overall,
this work supports the rationale for targeting Notch signalling
and further implicates Notch signalling in tumor physiology.
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